From mysteries to medicines: Drug development for fibrodysplasia ossificans progressiva

Expert Opinion on Orphan Drugs

Volumn 1, Issue 8, 2013, Pages 637-649

  Kaplan, Frederick S ^a,b,c   Pignolo, Robert J ^a,b   Shore, Eileen M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone morphogenetic protein receptors; Fibrodysplasia ossificans progressiva; Heterotopic endochondral ossification; Skeletal metamorphosis

Indexed keywords

ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1;

DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; HETEROTOPIC OSSIFICATION; HETEROZYGOSITY; HUMAN; NONHUMAN; OSSIFYING MYOSITIS; REVIEW; SOFT TISSUE INJURY; STEM CELL;

EID: 84896710829     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.825208     Document Type: Review

References (96)

1. Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br 1982;64:76-83.
2. Kaplan FS, Glaser DL, Shore EM, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005;3:183-8.
3. Kaplan FS, LeMerrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 2008;22:191-205.
4. Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol 2010;6:518-27.
5. Glaser DL, Rocke DM, Kaplan FS. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 1998;346:110-16
6. Lanchoney TF, Cohen RB, Rocke DM, et al. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr 1995;126:762-4.
7. Luchetti W, Cohen RB, Hahn GV, et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:21-5.
8. Scarlett RF, Rocke DM, Kantanie S, et al. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clin Orthop Relat Res 2004;423:275-9 . Viral illnesses can cause FOP flare-ups.
9. Cohen RB, Hahn GV, Tabas JA, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of 44 patients. J Bone Joint Surg Am 1993;75:215-19
10. Rocke DM, Zasloff M, Peeper J, et al. Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop 1994;301:243-8.
11. Kaplan FS, Glaser DL. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005;3:213-16
12. Kussmaul WG, Esmail AN, Sagar Y, et al. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthop 1998;346:104-9.
13. Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010;92:686-91.
14. Schaffer AA, Kaplan FS, Tracy MR, et al. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 2005;30:1379-85.
15. Shah PB, Zasloff MA, Drummond D, Kaplan FS. Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 1994;76:1442-50
16. Deirmengian GK, Hebela NM, OConnell M, et al. Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2008;90:366-74.
17. Kaplan FS, Strear CM, Zasloff MA. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop 1994;304:238-47.
18. Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009;30:379-90.
19. Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva (FOP). Pediatr Radiol 2001;31:307-14.
20. Shirkhoda A, Armin A-R, Bis KG, et al. MR imaging of myositis ossificans: variable patterns at different stages. J Magn Reson Imaging 1995;65:287-92
21. Einhorn TA, Kaplan FS. Traumatic fractures of heterotopic bone in patients who have fibrodysplasia ossificans progressiva. Clin Orthop 1994;308:173-7
22. Kaplan FS, Tabas JA, Gannon FH, et al. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J Bone Joint Surg (Am) 1993;75:220-30.
23. Pignolo RJ, Suda RK, Kaplan FS. The fibrodysplasia ossificans progressiva lesion. Clin Rev Bone Miner Metab 2005;3:195-200
24. Glaser DL, Economides AN, Wang L, et al. In vivo somatic cell gene transfer or an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003;85:2332-42.
25. Hegyi L, Gannon FH, Glaser DL, et al. Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. J Pathol 2003;201:141-8.
26. Gannon FH, Valentine BA, Shore EM, et al. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop 1998;346:19-25.
27. Gannon F, Kaplan FS, Olmsted E, et al. Differential immunostaining with bone morphogenetic protein (BMP) 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva and aggressive juvenile fibromatosis. Hum Pathol 1997;28:339-43.
28. Kaplan FS, Glaser DL, Shore EM, et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am 2007;89:347-57.
29. Gannon FH, Glaser D, Caron R, et al. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 2001;32:842-8.
30. Kan L, Lounev VY, Pignolo RJ, et al. Substance P signaling mediates BMP dependent heterotopic ossification. J Cell Biochem 2011;112:2759-72
31. Salisbury E, Rodenberg E, Sonnet C, et al. Sensory nerve induced inflammation contributes to heterotopic ossification. J Cell Biochem 2011;112:2748-58.
32. Suda RK, Billings PC, Egan KP, et al. Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells 2009;27:2209-19
33. Lounev V, Ramachandran R, Wosczyna MN, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am 2009;91:652-63.
34. Medici D, Shore EM, Lounev VY, et al. Conversion of vascular endothelial cells into multipotent stem-cell like cells. Nat Med 2010;12:1400-6.
35. Wosczyna MN, Biswas AA, Cogswell CA, Goldhamer DJ. Multipotent progenitors resident in skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J Bone Miner Res 2012;27:1004-17
36. Kaplan FS, Shore EM, Gupta R, et al. Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. Clin Rev Bone Miner Metab 2005;3:189-93.
37. Kan L, Hu M, Gomes WA, Kessler JA. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol 2004;165:1107-15
38. Kan L, Liu Y, McGuire TL, et al. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells 2009;27:150-6
39. Chakkalakal SA, Zhang D, Culbert AL, et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 2012;27:1746-56.
40. Kaplan FS, Chakkalakal SA, Shore EM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech 2012;5:756-62.
41. Yu PB. Deng, DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 2008;14:1363-9.
42. Lutwak L. Myositis ossificans progressiva: mineral, metabolic, and radioactive calcium studies of the effects of hormones. Am J Med 1964;37:269-93.
43. Kaplan F, Sawyer J, Connors S, et al. Urinary basic fibroblast growth factor: a biochemical marker for preosseous fibroproliferative lesions in patients with FOP. Clin Orthop 1998;346:59-65.
44. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005;116:654-61.
45. Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008;121:e1295-300.
46. Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005;3:201-4.
47. Rogers JG, Chase GA. Paternal age effect in fibrodysplasia ossificans progressiva. J Med Genet 1979;16:147-8.
48. Kaplan FS, McCluskey W, Hahn G, et al. Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg (Am) 1993;75:1214-20
49. Janoff HB, Muenke M, Johnson LO, et al. Fibrodysplasia ossificans progressiva in two half-sisters. Evidence for maternal mosaicism. Am J Med Genet 1996;61:320-4
50. Hebela N, Shore EM, Kaplan FS. Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. Clin Rev Bone Miner Metab 2005;3:205-8
51. Kaplan FS, Shore EM, Pignolo RJ. editors. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Consort FOP 2011;4:1-100.Available from: www.ifopa. org.
52. Rosenstirn JA. A contribution to the study of myositis ossificans progressiva. Ann Surg 1918;68:485-520; 591-637.
53. Levy CE, Lash AT, Janoff HB, Kaplan FS. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol 1999;8:29-33.
54. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38:525-7
55. Kaplan FS, Glaser DL, Pignolo RJ, Shore EM. A new era of fibrodysplasia ossificans progressiva (FOP): a druggable target for the second skeleton. Expert Opin Biol Ther 2007;7:705-12
56. Kaplan FS, Lounev V, Wang H, et al. Fibrodysplasia ossificans progressiva: a blueprint for the metamorphosis. Ann NY Acad Sci 2011;1237:5-10.
57. Kaplan F, Tabas JA, Zasloff MA. Fibrodysplasia ossificans progressiva: a clue from the fly? Calcif Tissue Int 1990;47:117-25.
58. Shafritz AB, Shore EM, Gannon FH, et al. Dysregulation of bone morphogenetic protein 4 (BMP4) gene expression in fibrodysplasia ossificans progressiva. N Engl J Med 1996;335:555-61.
59. Ahn J, Serrano de La Pena L, Shore EM, Kaplan FS. Paresis of a bone morphogenetic protein antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am 2003;85:667-74
60. Serrano de la Pena L, Billings PC, Fiori JL, et al. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 2005;20:1168-76
61. Fiori JL, Billings PC, Serrano de la Pena L, et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2006;21:902-9
62. Billings PC, Fiori JL, Bentwood JL, et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008;23:305-13
63. Shen Q, Little SC, Xu M, et al. The fibrodysplasia ossificans progressive R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009;119:3462-72.
64. Fukuda T, Kohda M, Kanomata K, et al. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 2009;284:7149-56
65. Kaplan FS, Pignolo RJ, Shore EM. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev 2009;20:399-407.
66. Bocciardi R, Bordo D, Di Duca M, et al. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Genet 2009;3:311-18
67. Carvalho DR, Navarro MMM, Martins B, et al. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients. Clin Genet 2010;77:171-6
68. Furuya H, Ikezoe K, Wang LX, et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A 2008;146A(4):459-63
69. Gregson CL, Hollingworth P, Williams M, et al. A novel ACVR1 mutation in the glycine/serinerich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 2011;48:654-8
70. Petrie KA, Lee WH, Bullock AN, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. Plos One 2009;4(3):e5005
71. Ratbi I, Borcciadi R, Regragui A, et al. Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva. Clin Rheum 2010;1:119-21
72. Takahashi M, Katagiri T, Furuya H, Hohjoh H. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Gene Ther 2012;19:781-5.
73. Whyte MP, Wenkert D, Demertzis J, et al. Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G C, p. G325A) in ACVR1. J Bone Miner Res 2011;27:729-37
74. Fukuda T, Kanomata K, Nojima J, et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 2008;377:905-9
75. Zhang D, Schwarz EM, Rosier RN, et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 2003;9:1593-604.
76. Groppe JC, Shore EM, Kaplan FS. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat Res 2007;462:87-92
77. Chaikaud A, Alfano I, Kerr G, et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 2012;287:36990-8.
78. Groppe JC, Wu J, Shore EM, Kaplan FS. In vitro analysis of the dysregulated R206H ALK2 Kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011;194:291-5
79. van Dinther M, Visser N, de Gorter DJ, et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblasts differentiation and bone formation. J Bone Miner Res 2010;25:1208-15
80. Song GA, Kim HJ, Woo KM, et al. Molecular consequences of the ACVR1 (R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 2010;285:22542-53
81. Nussinov R, Tsai C-J. Allostery in disease and drug discovery. Cell 2013;153:293-305
82. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9
83. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34
84. Gugala Z, Olmsted-Davis EA, Gannon FH, et al. Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type. Gene Ther 2003;10:1289-96
85. Fukuda T, Scott G, Komatsu Y, et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 2006;44:159-67
86. Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev 2009;20:409-18.
87. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008;4:33-41
88. Engers DW, Frist AY, Lindsley CW, et al. Synthesis and structure relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo [1.5-alpha]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett 2013;23(11):3248-52.
89. Mohedas AH, Xing X, Armstrong KA, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;DOI: 10.1021/cb300655w.
90. Kaplan J, Kaplan FS, Shore EM. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther 2011;19:786-90.
91. Zasloff MA, Rocke DM, Crofford LJ, et al. Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin Orthop 1998;346:121-9.
92. Shimono K, Tung W-E, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor- agonists. Nat Med 2011;17:454-60.
93. Kaplan FS, Shore EM. Derailing heterotopic ossification and RARing to go. Nat Med 2011;17:420-1 . A detailed rationale for the use of RAR-gamma agonists in early FOP flare-ups.
94. Olmsted-Davis E, Gannon FH, Ozen M, et al. Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol 2007;170:620-32
95. Maeder T. A few hundred people turned to bone. Atlantic Mon 1998;281:81-9.
96. IFOPA. Available from: www.ifopa.org